### Highlights of This Issue 3359

#### SPECIAL FEATURES

**CCR Translations**
- **3361**  [MET as a Target in Papillary Renal Cell Carcinoma](#)
  - André P. Fay, Sabina Signoretti, and Toni K. Choueiri
  - See related article, p. 3411

**CCR Perspectives in Drug Approval**
- **3364**  [U.S. Food and Drug Administration Inspections of Clinical Investigators: Overview of Results from 1977 to 2009](#)
  - Sonia K. Morgan-Linnell, David J. Stewart, and Razelle Kurzrock

**Statistics in Clinical Cancer Research**
- **3371**  [Blocking and Randomization to Improve Molecular Biomarker Discovery](#)
  - Li-Xuan Qin, Qin Zhou, Faina Bogomolniy, Liliana Villafania, Narciso Olvera, Magali Cavatone, Jaya M. Satagopan, Colin B. Begg, and Douglas A. Levine

**Molecular Pathways**
- **3379**  [Molecular Pathways: CDK4 Inhibitors for Cancer Therapy](#)
  - Mark A. Dickson
- **3384**  [Molecular Pathways: Niches in Metastatic Dormancy](#)
  - Kenji Yumoto, Matthew R. Eber, Janice E. Berry, Russell S. Taichman, and Yusuke Shiozawa

**Review**
- **3390**  [Infusions of Allogeneic Natural Killer Cells as Cancer Therapy](#)
  - Wing Leung

### HUMAN CANCER BIOLOGY

**3401**  [Efficient Identification of Mutated Cancer Antigens Recognized by T Cells Associated with Durable Tumor Regressions](#)
- Yong-Chen Lu, Xin Yao, Jessica S. Crystal, Yong F. Li, Mona El-Gamil, Colin Gross, Lindy Davis, Mark E. Dudley, James C. Yang, Yardena Samuels, Steven A. Rosenberg, and Paul F. Robbins

**3411**  [MET Is a Potential Target across All Papillary Renal Cell Carcinomas: Result from a Large Molecular Study of pRCC with CGH Array and Matching Gene Expression Array](#)
  - See related article, p. 3361

**3422**  [Prevailing Role of Contact Guidance in Intrastromal T-cell Trapping in Human Pancreatic Cancer](#)
- Natalie Hartmann, Nathalia A. Giese, Thomas Gielse, Isabel Poschke, Rienk Oftringa, Jens Werner, and Eduard Ryschich

**3434**  [Overexpression of Sirt7 Exhibits Oncogenic Property and Serves as a Prognostic Factor in Colorectal Cancer](#)
- Hongyan Yu, Wen Ye, Jiangxue Wu, Xiangqi Meng, Ran-ly Liu, Xiaofang Ying, Yi Zhou, Hui Wang, Changchuan Pan, and Wenlin Huang

### CANCER THERAPY: PRECLINICAL

**3446**  [Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma](#)
- Mohammad Atefi, Earl Avramis, Amanda Lassen, Deborah J.L. Wong, Lidia Robert, David Foulad, Michael Cerniglia, Bjorn Titz, Thlinie Chodon, Thomas G. Graeber, Begonya Comin-Anduix, and Antoni Ribas
Disruption of Follicular Dendritic Cells–Follicular Lymphoma Cross-talk by the Pan-PI3K Inhibitor BKM120 (Buparlisib)

Regorafenib Inhibits Colorectal Tumor Growth through PUMA-Mediated Apoptosis
Dongshi Chen, Liang Wei, Jian Yu, and Lin Zhang

Synergistic Anticancer Effects of Pam3CSK4 and Ara-C on B-Cell Lymphoma Cells
Sae-Kyung Lee, Jyh Y. Chwee, Cheryl A.P. Ma, Nina Le Bert, Caleb W. Huang, and Stephan Gasser

Importance of EGFR/ERCC1 Interaction Following Radiation-Induced DNA Damage
Giannaria Liccardi, John A. Hartley, and Daniel Hochhauser

Targeting PI3K/mTOR Overcomes Resistance to HER2-Targeted Therapy Independent of Feedback Activation of AKT

Old Drug New Use—Amoxapine and Its Metabolites as Potent Bacterial β-Glucuronidase Inhibitors for Alleviating Cancer Drug Toxicity
Ren Kong, Timothy Liu, Xiaoping Zhu, Syed Ahmad, Alfred L. Williams, Alexandra T. Phan, Hong Zhao, John E. Scott, Li-An Yeh, and Stephen T.C. Wong

In Vivo Fluorescence Lifetime Imaging for Monitoring the Efficacy of the Cancer Treatment
Yasaman Ardestirpour, Victor Chernomordik, Moinuddin Hassan, Rafal Zielinski, Jacek Capala, and Amir Gandjakhche

Improved Differentiation of Benign and Malignant Breast Tumors with Multiparametric 18Fluorodeoxyglucose Positron Emission Tomography Magnetic Resonance Imaging: A Feasibility Study
Katja Pinker, Wolfgang Bogner, Pascal Baltzer, Georgios Karanikas, Heinrich Magometschnigg, Peter Brader, Stephan Gruber, Hubert Bickel, Peter Dubsny, Zsuzsanna Bago-Horváth, Rupert Bartsh, Michael Weber, Siegfried Trattning, and Thomas H. Helbich

Treatment Response Evaluation Using 18F-FDOPA PET in Patients with Recurrent Malignant Glioma on Bevacizumab Therapy
Johannes Schwarzennegger, Johannes Czernin, Whitney B. Pope, Tristan Grogan, David Elashoff, Cheri Geist, Daniel H.S. Silverman, Michael E. Phelps, and Wei Chen

Variability in Assessing Treatment Response: Metastatic Colorectal Cancer as a Paradigm
Binsheng Zhao, Shing M. Lee, Hyun-Ju Lee, Yongqiang Tan, Jing Qi, Thorsten Persiegle, David P. Mozley, and Lawrence H. Schwartz

TP53 Mutation Spectrum in Breast Cancer Is Subtype Specific and Has Distinct Prognostic Relevance
Laxmi Silwal-Pandit, Hans Kristian Moen Vollan, Suet-Feung Chin, Oscar M. Rueda, Steven McKinney, Tomo Osako, David A. Quigley, Vessela N. Kristensen, Samuel Aparicio, Anne-Lise Borresen-Dale, Carlos Caldas, and Anita Langerød

A Phase I Trial of LY2510924, a CXCR4 Peptide Antagonist, in Patients with Advanced Cancer
Matthew D. Galsky, Nicholas J. Vogelzang, Paul Conkling, Eyas Raddad, John Polzer, Stephanie Roberson, John R. Stille, Mansoor Saleh, and Donald Thornton

Identification of Campath-1 (CD52) as Novel Drug Target in Neoplastic Stem Cells in 5q- Patients with MDS and AML
Katharina Blatt, Harald Herrmann, Gregor Hoermann, Michael Willmann, Sabine Cerny-Reiterer, Irina Sadovnik, Susanne Hemdlhofer, Berthold Streubel, Werner Rabitsch, Wolfgang R. Sperr, Matthias Mayerhofer, Thomas Rulicke, and Peter Valent
3603  Phase II Study of Cediranib in Patients with Advanced Gastrointestinal Stromal Tumors or Soft-Tissue Sarcoma
Ian Judson, Michelle Scurr, Kate Gardner, Barbra Collins, Helen Young, Juliane M. Jürgensmeier, and Michael Leahy

3613  Prognostic and Therapeutic Implications of Aromatase Expression in Lung Adenocarcinomas with EGFR Mutations
Mikihiro Kohno, Tatsuro Okamoto, Kenichi Suda, Mototsugu Shimokawa, Hirokazu Kitahara, Shinjiro Shimamatsu, Hirokazu Konishi, Tsukihisa Yoshida, Mitsuhiro Takenoyama, Tokujiro Yano, and Yoshihiko Maehara

3623  SNPs in PI3K-PTEN-mTOR and Brain Metastases in NSCLC—Letter
Abolfazl Avan, Mina Maftouh, Amir Avan, Carmelo Tibaldi, Paolo A. Zucali, and Elisa Giovannetti

3625  SNPs in PI3K-PTEN-mTOR and Brain Metastases in NSCLC—Response
Qianxia Li, Huihua Xiong, and Xianglin Yuan

ABOUT THE COVER
Loss of S6 phosphorylation as a biomarker of response to PI3K/mTOR pathway inhibition. The representative image shows immunohistochemical staining for phosphorylated S6 protein (ser235-236) in SUM190 breast cancer cell line xenografts treated with the pan-PI3K inhibitor BKM120. For details, see the article by O’Brien and colleagues on page 3507 of this issue.
Clinical Cancer Research

20 (13)


Updated version

Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/20/13

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.